¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"indirect complement fixation test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • breath holding test
    ¼ûÂü±â°Ë»ç, È£ÈíÁßÁö°Ë»ç
  • bronchial challenge test
    ±â°üÁöÀ¯¹ß°Ë»ç
  • clearance test
    û¼ÒÀ²½ÃÇè
  • clock-drawing test
    ½Ã°è±×¸®±â°Ë»ç
  • cold pressure test
    ÇÑ·©¾Ð¹Ú°Ë»ç
  • contraction stress test
    ¼öÃàÀڱذ˻ç
  • Coombs¡¯ test
    ÄñÁî°Ë»ç
  • coordination test
    ¼Õ¹ßÇùÁ¶±â´É°Ë»ç
  • cover-uncover test
    °¡¸²¾È°¡¸²°Ë»ç
  • creatinine clearance test
    Å©·¹¾ÆÆ¼´Ñû¼ÒÀ²°Ë»ç
  • catalase test
    īŻ¶ó¾ÆÁ¦°Ë»ç
  • challenge test
    À¯¹ß°Ë»ç
  • caloric test
    ¿Â¼ö´«¶³¸²°Ë»ç
  • chemiluminescence test
    È­Çй߱¤°Ë»ç
  • chi-square test
    Ä«ÀÌÁ¦°ö°ËÁ¤
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • basophil degranulation test
    È£¿°±â±¸Å»°ú¸³°Ë»ç
  • bead test
    ±¸½½½ÃÇè, ±¸½½°Ë»ç
  • bile solubility test
    ´ãÁó¿ëÇØµµ°Ë»ç
  • biliary drainage test
    ´ãÁó¹èÃâ°Ë»ç, ´ãÁó¹è¾×°Ë»ç
  • biological test
    »ý¹°ÇÐÀû½ÃÇè
  • blank test
    °ø½ÃÇè
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • blocking test
    Â÷´Ü½ÃÇè
  • blood test
    Ç÷¾×°Ë»ç
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • blood sugar test
    Ç÷´ç°Ë»ç
  • bone conduction test
    »ÀÀüµµ°Ë»ç, °ñµµ°Ë»ç
  • bone marrow function test
    °ñ¼ö±â´É°Ë»ç
  • breath holding test
    È£ÈíÁßÁö½ÃÇè, È£ÈíÁßÁö°Ë»ç
  • bulbocavernous evoked-response test
    ¸Á¿ïÇØ¸éü±ÙÀ¯µµ¹ÝÀÀ°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Draw-A-Person test(DAP)
    Àι°È­°Ë»ç
  • Du test
    Du °Ë»ç (ÁÖÀÇ : u ´Â À­Ã·ÀÚÀÓ)
  • Eleks gel-precipitin test
    ¿¤·ºÅ©ÇÑõÆòÆÇħ°­¹ý (µðÇÁÅ׸®¾Æµ¶¼Ò µ¿Á¤¹ý)
  • Falcon assay screening test
    ÆÈÄܺм®¼±º°½ÃÇè
  • Farnworth D-15 test
    ÆÄ¸¥¿ö½º15»ö»ó°Ë»ç
  • Farnworth-Munsell 100 hue test
    ÆÄ¸¥¿ö½º-¹®¼¿ 100»ö»ó°Ë»ç
  • Freda test
    ÇÁ·¹´Ù½ÃÇè
  • Frei s test
    ÇÁ¶óÀ̽ÃÇè<¹ÝÀÀ>
  • Frei test
    ÇÁ¶óÀ̽ÃÇè
  • Freis test
    ÇÁ¶óÀ̰˻ç
  • Friedman test
    ÇÁ¸®µå¸¸½ÃÇè
  • Frye test
    ÇÁ¶óÀ̽ÃÇè
  • GTT= glucose tolerance test
    ´çºÎÇÏ °Ë»ç.
  • Gelle test
    °Ö·¹°Ë»ç
  • Gerhardt ferric chloride test
    °Ô¸£Çϸ£Æ® ¿°È­Ã¶½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • complement typing
    º¸Ã¼Çüº°È­(úþܬûù)
  • complement unit
    º¸Ã¼´ÜÀ§(¡­Ó¤êÈ).
  • complement-mediated cytotoxicity
    º¸Ã¼ °ü·Ã¼º ¼¼Æ÷µ¶¼º(ÜÍô÷μ֤àõ á¬øàÔ¸àõ)
  • deficiency state, complement
    º¸Ã¼°áÇÌÁõ
  • dominant complement
    ¿ì¼ºº¸Ã¼(¡­ÜÍô÷).
  • endpiece of complement
    º¸Ã¼¸»Àý(ÜÍô÷ØÇï½).
  • heparin complement
    ÇìÆÄ¸°º¸Ã¼.
  • inactivation of complement
    º¸Ã¼ºñµ¿È­.
  • total hemolytic complement activity
  • alternating fixation
    ±³´ëÁÖ½Ã
  • anomalous fixation
    ÀÌ»óÁÖ½Ã
  • bifoveal fixation
    ¾ç¾ÈÁ߽ɿÍÁÖ½Ã
  • binocular fixation
    ¾ç¾ÈÁÖ½Ã(¡­ñ¼ãÊ).
  • capsular fixation
    ³¶³»°íÁ¤
  • central fixation
    Áß½ÉÁÖ½Ã
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
LTT lactose tolerance test; leucine tolerance test; limited treadmill test; lymphocyte transformation te...
SAT saliva alcohol test; satellite; serum antitrypsin; single-agent chemotherapy; slide agglutination te...
SRT sedimentation rate test; simple reaction time; sinus node recovery time; sitting root test; speech r...
ST esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor...
Hb Hemoglobin; Ç÷»ö¼Ò; 13 - 15 mg%
  1 gm ÆÄ±«½Ã Indirect Bilirubin 40 mg Áõ°¡
  = ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
IFI indirect immunofluorescence
IIF indirect immunofluorescence assay
IIF indirect immunofluorescence technique
E test Epsilometer test
ACP Alternative complement pathway
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blood test
    Ç÷¾× °Ë»ç, Ç÷¾× °Ë»ç¹ý
    Áúº´ÀÇ Áø´Ü, Ä¡·á ¹× ¿¹ÈÄ ÆÇÁ¤À» ¸ñÀûÀ¸·Î Ç÷¾×ÀÇ °¢Á¾ ¼ººÐÀ» °Ë»çÇÏ´Â ÀÏ. ¸ö ÀüüÀÇ Àå±â³ª Á¶Á÷¿¡ º´º¯ÀÌ ÀÖÀ¸¸é ÀÌµé ¼ººÐ¿¡ º¯È­°¡ ÀÖ°Ô µÇ¾î Áø´Ü¿¡ Å« µµ¿òÀ» ÁØ´Ù. ©ç ÇüÅÂÇÐÀû °Ë»ç¹ý : Ç÷¾×ÀÇ ¼¼Æ÷ÇÐÀû ¹× ÀÌÇÐÀûÀÎ ¼ºÁú°ú »óŸ¦ °Ë»çÇÏ´Â °ÍÀ¸·Î¼­ äÇ÷ÇÏ¿© ÀûÇ÷±¸ ¼ö, Ç÷»ö¼Ò·®, ÀûÇ÷±¸ ¿ëÀû°ú À̵鿡¼­ °è»êµÇ´Â °è¼ö¿Í ¹éÇ÷±¸ ¼ö, Ç÷¼ÒÆÇ ¼ö, ¸Á»ó ÀûÇ÷±¸ ¼ö µîÀ» °Ë»çÇÏ°í ¶Ç Ç÷¾× ÇÑ ¹æ¿ïÀ» ½½¶óÀÌµå ±Û¶ó½º¿¡ ¾ã°Ô ¹Ù¸¥ °ÍÀ» ¿°»öÇÏ¿© ¹éÇ÷±¸ÀÇ Á¾·ù, °¢Á¾ Ç÷±¸ÀÇ ÁúÀû º¯È­¸¦ Á¶»çÇÑ´Ù. ¶Ç ÃâÇ÷ ½Ã°£, ÀÀ°í ½Ã°£, ¸ð¼¼Ç÷°ü ÀúÇ× µîÀ» °Ë»çÇØ¼­ ÃâÇ÷ °æÇâ, Ç÷¾× Áúȯ, °¨¿°Áõ µîÀÇ Áø´Ü°ú °¢Á¾ ÁúȯÀÇ °æ°ú¿Í ¿¹ÈÄ ÆÇÁ¤¿¡ Å« µµ¿òÀÌ µÈ´Ù. ©è »ýÈ­ÇÐÀû °Ë»ç¹ý : Ç÷¾× ¼ÓÀÇ ¿©·¯ ¼ººÐÀ» »ýÈ­ÇÐÀû ¹æ¹ýÀ¸·Î ÃøÁ¤ÇÏ´Â °ÍÀ¸·Î Ç÷û ´Ü¹éÁú
  • bone conduction test
    °ñÀüµµ ½ÃÇè
  • Bonsignore test
    º»½Ã±×³ë ½ÃÇè
  • bracelet test
    ¿Ï·û ½ÃÇè
  • breakdown test
    ÆÄ±« ½ÃÇè
  • breath holding test
    È£Èí ÁßÁö ½ÃÇè
  • Brucellosis test
    ºê·ç¼¿¶óÁõ ½ÃÇè
  • butyric acid test
    ³«»ê ½ÃÇè
  • Callaways test
    Ķ·¯¿þÀÌ ½ÃÇè
    »ó¿Ï°ñ Å»±¸ÀÇ ½ÃÇè¹ýÀ¸·Î, °ßºÀ¿¡¼­ °Üµå¶ûÀ̸¦ °ÅÃÄ ÃøÁ¤ÇÑ ¾î±ú µÑ·¹´Â Å»±¸µÈ ÂÊÀÌ ´õ Å©´Ù
  • candida test
    ĵµð´Ù ½ÇÇè
  • Cantanis test
    ĭŸ´Ï ½ÃÇè
  • capillary fragility test
    ¸ð¼¼°ü Ãë¾à¼º ½ÃÇè, ¸ð¼¼Ç÷°ü Ãë¾à¼º ½ÃÇè
    Á¤¸Æ Ç÷·ù¸¸À» ÃæºÐÈ÷ Â÷´ÜÇÒ ¼ö ÀÖµµ·Ï Ç÷¾Ð´ë¸¦ 5ºÐ°£ °­ÇÏ°Ô Á¹¶ó¸Ç ÈÄ¿¡ ÀÌ·Î ÀÎÇÏ¿© »ý±ä ÇǺÎÀÇ Á¡ÃâÇ÷ÀÇ ¼ö¸¦ ¼¼¾î ¸ð¼¼°üÀÇ Ãë¾à¼ºÀ» °Ë»çÇÏ´Â °Í.
  • capillary resistance test
    ¸ð¼¼Ç÷°ü ÀúÇ×¼º ½ÃÇè
  • Cappagnolis test
    İÆÄ³î¸® ½ÃÇè
  • carbohydrate fermentation test
    ź¼öÈ­¹° ¹ßÈ¿ ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
complement 8 The next to the last essential component for cell lysis in the complement reaction sequence. It is a gamma-globulin with a molecular weight of 150,000 and a sedimentation coefficient of 8. It is present in trace amounts in serum and can be inhibited, like complement 1, by cation chelators.
(12 Dec 1998)
complement 9 The last component in the complement reaction sequence. It is an alpha-globulin present in serum as a trace, with a molecular weight of 80,000 and a sedimentation coefficient of 4.5. For cell lysis, it can be replaced by a metal chelator.
(12 Dec 1998)
complement activating enzymes <enzyme> Enzymes present in the complement system which activate one or more components in the system.
Registry number: EC 3.-
(12 Dec 1998)
complement activation The sequential activation of serum components c1 through c9, initiated by an erythrocyte-antibody complex or by microbial polysaccharides and properdin, and producing an inflammatory response.
(12 Dec 1998)
complement binding assay A test for the detection of immune complexes.
(05 Mar 2000)
complement chemotactic factor The activated complex of the fifth, sixth, and seventh components of complement (C567) which induces chemotaxis in the case of polymorphonuclear leukocytes.
(05 Mar 2000)
complement cytolysis inhibitor <protein> Vertebrate glycoprotein of uncertain function. Secreted as a 400 amino acid peptide, then cleaved to form two 200 amino acid peptides that are linked by a disulphide bridge.
Synonym: complement associated protein, complement cytolysis inhibitor, glycoprotein III.
(11 Jan 1998)
complement factor h <chemical> A beta-globulin that binds to complement 3b and makes ic3b (inactivated complement 3b) susceptible to cleavage by complement factor I. Complement factor h also acts as an alternative pathway complement inhibitor by interfering with the binding of properdin factor b to c3b.
Chemical name: Complement factor H
(12 Dec 1998)
complement factor I <enzyme> Serine proteinase that acts on ic3b (inactivated complement 3b) to cleave it into c3c and c3dg with the help of a trypsin-like proteolytic enzyme. Complement factor I was formerly called kaf, c3binf, or enzyme 3b inactivator.
Registry number: EC 3.4.21.45
(12 Dec 1998)
complement-fixing antibody Antibody that combines with and sensitises antigen leading to the activation of complement, which may result in cell lysis.
Synonym: CF antibody, sensitizing substance.
(05 Mar 2000)
complement haemolytic activity assay Usual screening assay for complement. Dilutions of the serum to be tested are added to antibody-coated erythrocytes and the percentage of lysis is measured. The values are expressed by ch50, haemolytic complement units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
(12 Dec 1998)
complement inactivators Serum proteins which act at key sites in the complement sequence to modulate or prevent the progression of the reaction. Absence of these factors leads to uncontrolled activation of the complement system with accompanying disease.
(12 Dec 1998)
complement membrane attack complex The assembly of complement plasma glycoproteins c5b, c6, c7, c8, and polymeric c9 as a group on biological membranes. The complex forms transmembrane channels which displace lipid molecules and other constituents, thus disrupting the phospholipid bilayer of target cells leading to cell lysis by osmotic leakage. The formation of the membrane attack complex is the terminal step in the complement cascade.
(12 Dec 1998)
complement pathway, alternative The complement activation sequence initiated by the activation of complement factor c3, which is triggered by the interaction of microbial polysaccharides and properdin without participation of an antigen-antibody reaction.
(12 Dec 1998)
complement pathway, classical The sequential activation of complement, initiated by antigen-antibody complex and the binding of complement factor c1q to the fc region of the antibody.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á